Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Autologous Natural Killer Cells in Subjects With Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03894579
Recruitment Status : Recruiting
First Posted : March 28, 2019
Last Update Posted : August 29, 2019
Sponsor:
Information provided by (Responsible Party):
NKMax America, Inc.

Brief Summary:
This is a non-randomized, dose escalating and open-labeled clinical trial to evaluate the safety of autologous natural killer cell (NK) infusions (IV) of "SNK01" in adults with plaque psoriasis. The primary objective of this study is to investigate the safety and tolerability of four infusions of "SNK01" in subjects with plaque psoriasis. Secondary objective is preliminary efficacy of "SNK01" in subjects with plaque psoriasis.

Condition or disease Intervention/treatment Phase
Plaque Psoriasis Biological: Study Product: SNK01 Phase 1

Detailed Description:
Nine (9) subjects, male or female, aged 18 years or older will be enrolled in the study, all of whom will receive "SNK01" without placebo control. There are three (3) subjects in each of the three (3) cohorts. The SNK01 study product will be administered at the following doses using dose escalating rules: Cohort 1 will receive 4 weekly infusions of 1 billion cells, Cohort 2 will receive 4 weekly infusions of 2 billion cells, and Cohort 3 will receive 4 weekly infusions of 4 billion cells. Length of participation, per subject, is approximately 12 weeks. The primary endpoint for safety is dose-limiting toxicity (DLT) which is defined as TEAE of grade ≥ 3 considered related to SNK01. Secondary safety endpoints include other adverse events (graded according to National Cancer Institute's Common Toxicity Criteria for Adverse Events [NCI-CTCAE v 5.0]), vital sign measurements, clinical laboratory tests and physical examination. Preliminary efficacy will be measured by Psoriasis Area Severity Index (PASI) and by the Physician's Global Assessment (PGA.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 9 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Non-randomized, open label, single center trial. Subjects will receive SNK01 using a 3 + 3 dose escalating design
Masking: None (Open Label)
Masking Description: open-label
Primary Purpose: Treatment
Official Title: Phase 1, Open-Label, Safety Study of Escalating Doses of Ex Vivo Expanded, Autologous Natural Killer Cells in Subjects With Plaque Psoriasis
Actual Study Start Date : July 24, 2019
Estimated Primary Completion Date : December 15, 2019
Estimated Study Completion Date : January 15, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: SNK01
SNK01 infused weekly for 4 consecutive weeks
Biological: Study Product: SNK01
SNK01 administered using an intravenous line (IV) to all patients at weeks 1, 2, 3, and 4




Primary Outcome Measures :
  1. The primary endpoint for safety is the dose-limiting toxicity (DLT) [ Time Frame: From enrollment to end of treatment at 8 Weeks ]
    DLT is a TEAE of grade ≥3 considered related to SNK01


Secondary Outcome Measures :
  1. Preliminary Efficacy by Physician Global Assessment (PGA) [ Time Frame: From enrollment to end of treatment at 8 Weeks ]
    The Physician Global Assessment (PGA) is a 6-point scoring system used to assess disease severity at a given time point. The PGA is a six-point score that summarizes the overall quality (erythema, scaling and thickness) and extent of Psoriasis plaques where (0) is clear, (1) minimal, (2) mild, (3) moderate, (4) severe, and (5) being very severe psoriasis. Change in score from baseline through Week 8 will be assessed.

  2. Preliminary Efficacy by Psoriasis Area and Severity Index (PASI) [ Time Frame: From enrollment to end of treatment at 8 Weeks ]
    Psoriasis Area and Severity Index (PASI) is the most widely used tool for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease). Change in score from baseline through Week 8 will be assessed.

  3. Secondary Safety Measures: Other Non-DLT Adverse Events [ Time Frame: From enrollment to end of treatment at 8 Weeks ]
    Frequency and type of Non-DLT adverse events (graded according to National Cancer Institute's Common Toxicity Criteria for Adverse Events [NCI-CTCAE v 5.0]),



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subjects will be considered eligible for participation in the study if all the following inclusion criteria are satisfied:

  1. Informed consent obtained before any "trial-related activities" (Trial-related activities are any procedure that would not have been performed during normal management of the subject)
  2. Diagnosis of plaque psoriasis for at least 6 months with at least one psoriatic plaque measuring between 2 cm and 5 cm at the time of screening
  3. If female, subject is either not of childbearing potential (postmenopausal for at least 1 year or surgically sterile) or is of childbearing potential and is using approved method of birth control throughout study and for 1 month after last dose of study drug. Approved methods of birth control include the following:

    1. Condoms, sponge, foams, jellies, diaphragm, or intrauterine device (IUD)
    2. Hormonal contraceptives for 90 days prior to study drug administration
    3. A vasectomized partner
  4. Subject must be able and willing to provide written informed consent and comply with requirements of this study protocol

    Following Eligibility & Consent:

  5. Subject must be able to donate 130 ml to 490 ml of blood for NKMax America to obtain an adequate number of autologous NK cells necessary to establish the final investigational product
  6. Successful establishment of the final NK product, or "study therapy", established by NKMax America

Exclusion Criteria:

Subjects who fulfill any of the following criteria will not be recruited into the study:

  1. Subjects with severe medical condition(s) that in the view of the investigator prohibits participation in the study
  2. Subject has Netherton's syndrome or other genodermatoses that results in a defective epidermal barrier
  3. Subjects who have applied topical medication (prescription or over-the-counter) for the treatment of psoriasis to their body within 7 days of the baseline visit
  4. Subjects who have taken cyclosporine, methotrexate, immuran, oral retinoids, chemotherapeutic agents, anti-inflammatory biologics (e.g., alefacept, etanercept, etc.), or oral calcineurin inhibitors within 28 days of the whole blood donation visit for the establishment of the investigational product
  5. Subjects who are unable to hold their current psoriasis medications for the period of time indicated (at least 7 days for topical medications, at least 28 days for oral or injectable medications) without significant worsening of their psoriasis
  6. Immunocompromised subjects (e.g., lymphoma, HIV/AIDS, Wiskott-Aldrich Syndrome) or subjects with a history of malignant disease (excluding non-melanoma skin cancer) as determined by the participant's medical history
  7. Subjects receiving phototherapy (e.g., ultraviolet light B [UVB], psoralen plus ultraviolet light A [PUVA]) within 28 days of the baseline visit.
  8. Subjects with a history of psychiatric disease or history of alcohol or drug abuse that would interfere with the ability to comply with the study protocol.
  9. Subjects with significant concurrent medical condition(s) at screening that in the view of the investigator prohibits that in the view of the investigator prohibits participation in the study (e.g., severe concurrent allergic disease, condition associated with malignancy, and condition associated with immunosuppression)
  10. Subjects with an active bacterial, viral or fungal skin infection (excluding nail fungus)
  11. Ongoing participation in an investigational drug trial
  12. Presence of psoriasis with exfoliative erythroderma or presence of guttate psoriasis, primary palmoplantar psoriasis, or pustular psoriasis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03894579


Contacts
Layout table for location contacts
Contact: Vanessa Teachout 619-301-1387 vteachout@nkmaxamerica.com
Contact: Michael Bayer 949-290-8404 mbayer@nkmaxamerica.com

Locations
Layout table for location information
Mexico
Hospital Angeles Recruiting
Tijuana, BC, Mexico, 22010
Contact: Vanessa Teachout    619-301-1387    vteachout@nkmaxamerica.com   
Sub-Investigator: Cesar Amescua, MD         
Sponsors and Collaborators
NKMax America, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Daniela Gutiérrez, MD Hospital Angeles Tijuana

Layout table for additonal information
Responsible Party: NKMax America, Inc.
ClinicalTrials.gov Identifier: NCT03894579    
Other Study ID Numbers: SNK01-MX03
First Posted: March 28, 2019    Key Record Dates
Last Update Posted: August 29, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by NKMax America, Inc.:
natural killer cells
autologous
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases